Actelion Ltd. Launches VALCHLOR (Mechlorethamine) Gel 0.016% In The U.S.
Published: Nov 18, 2013
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Actelion (SIX: ATLN) announced today that VALCHLOR™ (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine, is now available for patients in the United States (US). VALCHLOR, a gel which is applied topically once a day, is an alkylating drug indicated to treat patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy. VALCHLOR is an orphan drug that was acquired by Actelion US Holding Company, a subsidiary of Actelion Ltd., on September 18, 2013 as part of a merger with Ceptaris Therapeutics, Inc. VALCHLOR is distributed in the US by Accredo Specialty Pharmacy.
Help employers find you! Check out all the jobs and post your resume.